We observed that increasing the dose of palovarotene required to maintain the long-term suppression of tumor growth negatively affected skeletal growth in mice (Figure 2), suggesting that high doses and long-term administration of the RARγ agonist in this mouse model have adverse effects on skeletal cells such as chondrocytes and osteoblasts. This evidence concerns the gene RARG and neoplasm.